SLC5A2 and hydrops fetalis: In addition to lowering blood glucose, SGLT-2 inhibitors also have the power to reduce the risk of cardiovascular outcomes and mortality (Mascolo et al., 2021), especially when HF patients can obtain benefits from therapy treatment by dapagliflozin and empagliflozin (Packer et al., 2020; Butt et al., 2021).